The pharmaceutical industry, the state and the NHS

The New Sociology of the Health Service

Volumn , Issue , 2009, Pages 99-120

  Abraham, John ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960566158     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9780203879740     Document Type: Chapter

References (107)

1. Abraham, J. (1994a) 'Negotiation and accommodation in expert medical risk assessment and regulation', Policy Sciences, 27: 53-76.
2. Abraham, J. (1994b) 'Bias in science and medical knowledge', Sociology, 28:717-36.
3. Abraham, J. (1995a) Science, Politics and the Pharmaceutical Industry, London:UCL Press.
4. Abraham, J. (1995b) 'The production and reception of scientific papers in the medical-industrial complex', British Journal of Sociology, 46: 167-90.
5. Abraham, J. (2002a) 'Do we need a political sociology of medicine?', paper presented at British Sociological Association Medical Sociology Conference, York, 8 September.
6. Abraham, J. (2002b) 'Transnational industrial power, the medical profession and the regulatory state', Social Science and Medicine, 55: 1671-90.
7. Abraham, J. (2007) 'Neo-liberal corporate bias as a framework for understanding UK pharmaceuticals regulation', Social Theory and Health, 5: 161-75.
8. Abraham, J. and Davis, C. (2006) 'Testing times', Social History of Medicine, 19:127-47.
9. Abraham, J. and Davis, C. (2007) 'Interpellative sociology of pharmaceuticals:problems and challenges for innovation and regulation in the 21st century', Technological Analysis and Strategic Management, 19: 387-402.
10. Abraham, J. and Lewis, G. (2002) 'Citizenship, medical expertise and the capitalist regulatory state in Europe', Sociology, 36: 67-88.
11. Abraham, J. and Reed, T. (2002) 'Progress, innovation and regulatory science', Social Studies of Science, 32: 337-69.
12. Abraham, J. and Sheppard, J. (1999) The Therapeutic Nightmare, London:Earthscan.
13. Aldcroft, D.H. (1986) The British Economy, Sussex: Harvester.
14. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, Arlington: APA.
15. Annandale, E. (1998) The Sociology of Health and Medicine, Cambridge: Polity.
16. Anon. (1998a) 'Viagra breaks all records in the US', Scrip, 2331: 20.
17. Anon. (1998b) 'US insurers turn down Viagra citing lack of safety data', Scrip, 2351: 14.
18. Anon. (1998c) 'Viagra recommended for EC approval', Scrip, 2338/39: 36.
19. Anon. (1998d) 'No Viagra reimbursement in EU?', Scrip, 2351: 3.
20. Anon. (1999a) 'UK rules DoH Viagra circular unlawful', Scrip, 2441: 4.
21. Anon. (1999b) 'No flexibility in UK NICE advice', Scrip, 2439: 6.
22. Anon. (2001a) 'Why not zanamivir?' Drugs and Therapeutics Bulletin, 39: 9-10.
23. Anon. (2001b) 'Effectiveness, efficiency and NICE', British Medical Journal, 322:934-44.
24. Association of the British Pharmaceutical Industry (ABPI) (1970) 'Legislation:Medicines Commission', ABPI Annual Report, 1969-70: 9.
25. ABPI (1993) A Guide to the Pharmaceutical Price Regulation Scheme, London:ABPI.
26. Audit Commission (1994) A Prescription for Improvement, London: HMSO.
27. BBC News 24 (2004) 'Billion-pound price cut won for NHS medicine bill', news.bbc.co.uk, 3 November (accessed online 20 July 2008).
28. BBC News 24 (2006a) 'Woman wins Herceptin court fight', news.bbc.co.uk, 12 April (accessed online 20 July 2008).
29. BBC News 24 (2006b) 'Herceptin: was patient power key?' news.bbc.co.uk, 9 June 2006 (accessed online 20 July 2008).
30. BBC News 24 (2007) 'Alzheimer's drugs remain limited', news.bbc.co.uk, 10 August (accessed online 20 July 2008).
31. BBC News 24 (2008) 'Ministers seek to cut NHS drugs budget', news.bbc.co.uk, 7 January (accessed online 20 July 2008).
32. BBC online (1999) 'Drug companies join flu protest', news.bbc.co.uk, 6 October (accessed online 20 July 2008).
33. BBC online (2001) 'Guidance over anti-flu drug "wrong"', news.bbc.co.uk, 15 February (accessed online 20 July 2008).
34. Binns, T.B. (1980) 'The Committee on the Review of Medicines', British Medical Journal, 281: 1614-15.
35. Britten, N. (2001) 'Prescribing and the defence of clinical autonomy', Sociology of Health and Illness 23: 478-96.
36. Britten, N. (2008) Medicines and Society, Basingstoke: Palgrave.
37. Bruce, M. (1961) The Coming of the Welfare State, London: Batsford.
38. Castellanos, X. (2002) 'Development trajectories of brain volume abnormalities in children and adults with ADHD', Journal of the American Medical Association, 288: 1740-48.
39. Collier, J. (1985) 'Licensing and provision of medicines in the UK', Lancet, 326:377-80.
40. Collier, J. (1989) The Health Conspiracy, London: Century.
41. Conrad, P. and Potter, D. (2000) 'From hyperactive children to ADHD adults', Social Problems, 47: 559-82.
42. Crinson, I. (2004) 'The politics of regulation within the "modernized" NHS', Critical Social Policy, 24: 30-49.
43. Delamothe, T. (1989) 'Drug watchdogs and the drug industry', British Medical Journal, 299: 151-52.
44. Department of Health (DoH) (1994a) The NHS Drugs Budget Cm2683, London:HMSO.
45. DoH (1994b) Prescription Cost Analysis, London: Government Statistical Service.
46. DoH (2002) Cost Effective Provision of Disease Modifying Therapeis for People with Multiple Sclerosis, London: TSO.
47. DoH (2001) The Expert Patient, London: HMSO.
48. DoH (2003) Prescription Cost Analysis, London: Government Statistical Service.
49. Elston, M. (1991) 'The politics of professional power', in J. Gabe, M. Calnan and M. Bury (eds) The Sociology of the Health Service, London: Routledge.
50. Fox, N.J., Ward, K.J. and Rourke, A.J. (2005) 'The "expert patient"', Social Science and Medicine, 60: 1299-309.
51. Gabe, J. (ed.) (1991) Understanding Tranquilliser Use, London: Routledge.
52. Gabe, J. and Bury, M. (1996) 'Halcion nights', Sociology, 30: 447-69.
53. Griffin, J.P. and Long, J.R. (1981) 'New procedures affecting the conduct of clinical trials in the UK', British Medical Journal, 283: 481.
54. Harding, R. (2001) 'Unlocking the brain's secrets', Family Circle, 20 November:10-11.
55. Healy, D. (2004) Let Them Eat Prozac, London: New York University Press.
56. Healy, D. (2006) 'The new medical oikumene', in A. Petryna, A. Lakoff and A. Kleinman (eds) Global Pharmaceuticals, London: Duke University Press.
57. Herxheimer, A. (2003) Relationships between the pharmaceutical industry and patients' organizations', British Medical Journal, 326: 1208-10.
58. HMSO (1950) The Second Interim Report of the Joint Committee on Prescribing, London: HMSO.
59. House of Commons Health Committee (HCHC) (1994) The NHS Drugs Budget, London: HMSO.
60. HCHC (2002) National Institute for Clinical Excellence, London: TSO.
61. HCHC (2005) The Influence of the Pharmaceutical Industry, London: TSO.
62. Lexchin, J. (1993) 'Interactions between physicians and the pharmaceutical industry', Journal of the Canadian Medical Association, 149: 1401-7.
63. Lexchin, J., Bero, L.A., Djulbegovic, B. and Clark, O. (2003) 'Pharmaceutical industry sponsorship and research outcomes and quality', British Medical Journal, 326: 1167-70.
64. Lumley, C.E., Walker, S.R. and Hall, G.C. (1986) 'The under-reporting of adverse drug reactions seen in general practice', Pharmaceutical Medicine, 1: 205-12.
65. Mann, R.D. (1984) Modern Drug Use, Lancaster: MTP Press.
66. McIntyre, A. (1999) Key Issues in the Pharmaceutical Industry, Chichester: John Wiley.
67. Medawar, C. (1992) Power and Dependence, London: Social Audit.
68. Medawar, C. and Hardon, A. (2004) Medicines out of Control? Amsterdam:Askant.
69. Millar, J.S. (2001) 'Consultations owing to adverse drug reactions in a single practice', British Journal of General Practice, 51: 130-1.
70. New, B. (1996) 'The rationing agenda in the NHS', British Medical Journal, 312:1593-601.
71. NICE (1999) National Institute for Clinical Excellence: Framework Document, London: DoH.
72. NICE (2002) Beta Interferon and Glatiramer Acetate for the Treatment of Multiple Sclerosis, London: DoH.
73. O'Donovan, O. (2007) 'Corporate colonization of health activism?' International Journal of Health Services, 37: 711-33.
74. Office of Fair Trading (2007) The Pharmaceutical Price Regulation Scheme: an OFT market study, London: OFT.
75. Pharmaceutical Society of Great Britain (PSGB) (1950a) 'Annual report of the ABPI', Pharmaceutical Journal, 164: 301.
76. PSGB (1950b) 'Pharmaceutical industry and export drive', Pharmaceutical Journal, 164: 11.
77. PSGB (1954) 'ABPI annual dinner', Pharmaceutical Journal, 172: 312.
78. PSGB (1956a) 'Recruitment by the industry', Pharmaceutical Journal, 176: 1.
79. PSGB (1956b) 'British pharmaceutical industry', Pharmaceutical Journal, 176: 239.
80. PSGB (1962a) 'Clinical trials of drugs', Pharmaceutical Journal, 188: 429.
81. PSGB (1962b) 'Drug toxicity', Pharmaceutical Journal, 189: 523-4.
82. PSGB (1962c) '"Magnificent" export performance', Pharmaceutical Journal, 189:445.
83. PSGB (1963a) 'Committee on Safety of Drugs: members and terms of reference', Pharmaceutical Journal, 190: 534.
84. PSGB (1963b) 'Committee on Safety of Drugs: memo to manufacturers and importers', Pharmaceutical Journal, 191: 433.
85. PSGB (1967) 'Safety of drugs', Pharmaceutical Journal, 199: 59-60.
86. PSGB (1968a) 'The Medicines Bill in committee', Pharmaceutical Journal, 200:334-45.
87. PSGB (1968b) 'Medicines Bill', Pharmaceutical Journal, 200: 368-89.
88. PSGB (1970) 'Medicines Act reassurance for manufacturers', Pharmaceutical Journal, 204: 48.
89. Public Accounts Committee (1983) Dispensing of Drugs in the NHS, London:HMSO.
90. Public Records Office (PRO) (1950a) MH133/76 Note of discussion on 8 June between MoH and ABPI.
91. PRO (1950b) MH133/76 Memorandum from J.S. Walmsley, Secretary of the PAGB to the MoH regarding the Second Interim Report of the JCP, 14 June.
92. PRO (1950c) MH133/76 Letter from Sir J.H. Woods, Board of Trade, to Sir William Douglas, MoH, 20 July.
93. PRO (1950d) MH133/76 Letter, Sir William Douglas to Sir J. Woods, Board of Trade, 28 July.
94. PRO (1951) MH58/688 Review of Drug Legislation.
95. Sadler and Dent (2002) 'From guidance to practice-why NICE is not enough', British Medical Journal, 324: 842-5.
96. Sainsbury Committee (1967) Report of the Committee of Enquiry into the Relationship of the Pharmaceutical Industry with the National Health Service, Cmnd 3410, London: HMSO.
97. Scrip (1988a) World Pharmaceutical News, 1279: 3.
98. Scrip (1988b) World Pharmaceutical News, 1270: 24.
99. Scrip (1991) World Pharmaceutical News, 1635: 2.
100. Silverman, M. and Lee, P.R. (1974) Pills, Profits and Politics, Berkeley: California U.P.
101. Sklair, L. (1991) Sociology of the Global System, London: Harvester.
102. Sudlow, C. and Counsell, C. (2003) 'Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis', British Medical Journal, 326:388-92.
103. Taylor, D. and Bury, M. (2007) 'Chronic illness, expert patients and care transition', Sociology of Health and Illness, 29: 27-45.
104. Topol, E.J. (2004) 'Failing the public health-rofecoxib, Merck, and the FDA', New England Journal of Medicine, 351: 1707-9.
105. Wade, O.L. (1983) 'Achievements, problems and limitations of regulatory bodies', in D. Farrell (ed.) Medicines Review Worldwide, London: British Institute of Regulatory Affairs.
106. Walker, S.R. and Lumley, C.E. (1987) 'Reporting and under-reporting'. in R.D. Mann (ed.) Adverse Drug Reactions, Carnforth: Parthenon.
107. Wheeler, D.E. (1964) 'President's statement', ABPI Annual Report, (1963-64): 2-3.